CD276 and breast carcinoma: Given its stable and strong expression, B7-H3 represents an attractive target for immunotherapies, including bsAbs such as CC-3 (B7-H3xCD3), currently under clinical evaluation for treatment of CRC, breast cancer, sarcoma and penile carcinoma (NCT05999396) [19].